The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Barchart on MSN6h
This Penny Stock Just Doubled on Clinical Trial Results. Analysts Think It Can Surge 266% From Here.Biotechnology is a high-risk, high-reward landscape where innovation determines success. Yet, occasionally, a small player ...
Wells Fargo analyst Richard Garchitorena maintained a Buy rating on Corteva (CTVA – Research Report) yesterday and set a price target of ...
Mizuho (NYSE:MFG) analysts increased the price target for Corteva Inc. (NYSE:CTVA) shares to $71.00, up from the previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback